Based on DESTINY‐Breast01 data, T‐DXd received conditional approval from the European Medicines Agency (EMA) on January 18, 2021, as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2‐positive breast cancer who have received at least two prior anti‐HER2‐based therapies. Here, ERBB2 is linked to breast carcinoma.